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Abstract
Background: Patient organisations may be exposed to conflicts of interest and undue influence
through pharmaceutical industry (Pharma) donations. We examined advertising and disclosure of
financial support by pharmaceutical companies on the websites of major patient organisations.
Method: Sixty-nine national and international patient organisations covering 10 disease states
were identified using a defined Google search strategy. These were assessed for indicators of
transparency, advertising, and disclosure of Pharma funding using an abstraction tool and inspection
of annual reports. Data were analysed by simple tally, with medians calculated for financial data.
Results:  Patient organisations websites were clear about their identity, target audience and
intention but only a third were clear on how they derived their funds. Only 4/69 websites stated
advertising and conflict of interest policies. Advertising was generally absent. 54% of sites included
an annual report, but financial reporting and disclosure of donors varied substantially. Corporate
donations were itemised in only 7/37 reports and none gave enough information to show the
proportion of funding from Pharma. 45% of organisations declared Pharma funding on their website
but the annual reports named more Pharma donors than did the websites (median 6 vs. 1). One
third of websites showed one or more company logos and/or had links to Pharma websites. Pharma
companies' introductions were present on 10% of websites, some of them mentioning specific
products. Two patient organisations had obvious close ties to Pharma.
Conclusion: Patient organisation websites do not provide enough information for visitors to
assess whether a conflict of interest with Pharma exists. While advertising of products is generally
absent, display of logos and corporate advertisements is relatively common. Display of clear
editorial and advertising policies and disclosure of the nature and degree of corporate donations is
needed on patient organisations' websites. An ethical code to guide patient organisations and their
staff members on how to collaborate with Pharma is also necessary, if patient organisations are to
remain independent and truly represent the interests and views of patients. As many organizations
rely on Pharma donations, self-regulation may not suffice and independent oversight bodies should
take the lead in requiring this.
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Background
Patient advocacy and support organisations (hereafter
'patient organisations') are important in raising awareness
of particular conditions, disseminating information about
them, promoting the interests of patients and their carers
and supporting them. Patients therefore tend to trust
these organisations to act on their behalf in an unbiased
manner [1]. However, relationships of patient organisa-
tions to pharmaceutical companies can compromise their
independence (Table 1).
Since pharmaceutical companies (Pharma) and patient
organisations have some interests in common, it is not
surprising that funding relationships have developed
between them [2]. However, at the same time, Pharma's
competing and overriding responsibility to its sharehold-
ers based on ability to sell products may conflict with the
best interests of patients [1,3,4]. Patient organisations
offer Pharma two benefits: an avenue for influencing
patients about prescription medicines which may not be
advertised to the public (except notably in the USA and
New Zealand); and a surrogate pressure group for influ-
encing prescribers, policy makers and regulatory agencies
on access to and use of their products. The industry has
been accused of establishing its own 'patient organisa-
tions' in the past to suit its own agenda [3-5].
Recently the UK House of Commons Health Committee
Enquiry into 'The Influence of the Pharmaceutical Indus-
try' [6] noted that the level of support which patient
organisations receive from Pharma is not known and that
such groups need to openly declare "all significant fund-
ing and gifts in kind". Partly in response to these concerns,
the Association of British Pharmaceutical Industry (ABPI)
has revised its code of practice, now requiring all members
to disclose "any involvement a pharmaceutical company
has with a patient organisation". In particular, companies
"must make public by means of information on their
websites or in their annual report a list of patient organi-
sations to which they provide financial support" [7,8].
Since they are not required to state the level or nature of
the support, this 'disclosure' is thin. The government's
response on disclosure by the patient organisations them-
selves was to leave this to self-regulation [9].
Others have also made the case for patient organisations
to maintain their independence while still receiving and
disclosing financial and other support from Pharma
[1,4,10]. It is important for patients to know for them-
selves what interactions a particular patient organisation
has with such companies so that they can judge whether it
may be unduly influenced. The best approach in such
cases is openness and disclosure. How much is disclosed
has not been systematically studied although attention
has been drawn to inadequacies. For example 20 of 67
Italian breast cancer patient groups had received funds
from pharmaceutical companies but only 5 had conflict
of interest statements [11].
To gauge the scope of the problem, we have examined dis-
closure of financial support and overt sponsorship, as well
as advertising by companies on the websites of major
national and international patient organisations.
Methods
Websites for national and international patient organisa-
tions (patient organisations) based in the USA, UK, Aus-
tralia, Canada, and South Africa were identified for ten
major health conditions: cancer, heart disease, diabetes,
asthma, cystic fibrosis, epilepsy, depression, Parkinson's
disease, osteoporosis, rheumatoid arthritis – serious
chronic conditions in which drug treatment is important.
Additional inclusion criteria were that the patient organi-
sation:
• meet the membership criteria of the International Asso-
ciation of Patient Organizations (IAPO) (see below)
• be national or international (global) in nature (not
local, regional or supranational e.g. European)
Table 1: Relationships between pharmaceutical companies and patient organisations with potential for conflicts of interest or loss of 
independence
 Monetary donations to the patient organisation
 Payment of conference registration fees for patient organisation representatives
 Payment for conference travel and accommodation for patient organisation representatives
 Provision of non-educational gifts e.g. calendars, pens
 Funding to hold local or international conferences
 Funding of educational initiatives and meetings
 Sponsoring research grants and study fellowships administered by the patient organisation for scientists in the field
 Funding for core administrative functions
 Donations in kind e.g. facilities, administration, training materials, books for libraries, website design
 Provision of advocacy and educational materialBMC Public Health 2006, 6:201 http://www.biomedcentral.com/1471-2458/6/201
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• be all-encompassing towards the condition of interest
(not restricted to a particular form of the disease or a par-
ticular population group)
• be intended primarily for patients/carers in the country
where the website was hosted (except for international
patient organisations)
and that the website be in English and hosted in the USA,
UK, Australia, Canada, or South Africa.
The membership criteria of the IAPO are that patient
organisations should be non-profit and non-governmen-
tal, legally constituted, an international, regional,
national or local organization, or an umbrella group; and
demonstrate commitment to patients and be patient-
driven (governed by patients, or have patients as most vot-
ing members or have a governance structure which solicits
and is responsive to patient needs and views).
An assessment tool was developed for indicators of struc-
tural quality, general advertising, annual report availabil-
ity, and pharmaceutical company funding, advertising or
other involvement [see Additional file 1]. For structural
quality indicators the assessment tool incorporated the
Transparency and Accountability domains of the pro-
posed 'Quality Criteria for Health Related Websites of the
European Union' [12].
Websites were identified in the last week of December
2005 using Google [13] with the following search strat-
egy:
"<disease term> international association OR society OR
organisation OR organization OR foundation OR group
OR support OR trust OR charity site:<country domain>"
The disease terms were cancer, heart, diabetes, asthma,
epilepsy, depression, Parkinson's, "cystic fibrosis", oste-
oporosis and arthritis, and the country domains were org,
uk, ca, au, za.
The first 50 hits of each search were examined by KT to
identify potential eligible patient organisations. These
were 'validated' by DB. DB and KT each evaluated the
websites in January 2006 using the assessment tool. Dif-
ferences were resolved through consensus, with AH as
arbiter where opinions still differed.
Advertisements
Banner advertisements, defined as 'third-party website
advertisements which are an apparent source of income
for the host organisation', were examined. We excluded
charity shopping promotions which lead visitors to third-
party online shopping or credit card sites where a percent-
age of spending is donated back to the patient organisa-
tion. We also excluded advertising of products from the
organisation's merchandising arm.
Financial summaries
Financial data on the net assets, total annual revenue
(income) and income from membership dues and corpo-
rate donations were extracted from annual reports,
excluding donations in kind and donations from founda-
tions e.g. Amgen and GSK Foundations. Values were con-
verted to US dollars using the interbank currency rate for
01/01/2006 on Oanda.com [14] [accessed Jan. 2006]
without discounting or adjustment for inflation since
these values were only being used as a rough measure of
organisation size. Assets and revenue are reported to 2 sig-
nificant figures. Where data were given the ratio of mem-
bership dues and corporate donations to annual revenue
was taken to indicate the importance of these revenue
sources to the organisation's work.
Data analysis
Data were analysed using SPSS v13 (SPSS Inc., Chicago,
USA) with Excel 2003 (Microsoft Inc., Redmond, USA)
used for financial calculations. Simple tally and cross-tab-
ulation was used for individual items, with calculation of
medians for financial data. Since the study was descriptive
and hypothesis-generating, formal statistical tests were
not applied.
Results
Of an initial 107 websites, 69 met our inclusion criteria
(Figure 1). Table 2 lists the organisations and their URLs.
The data are presented according to indicators of website
quality, advertising, finances and disclosure of pharma-
ceutical company relationships.
Structural quality indicators
Almost all the patient organisation websites (>96%) were
transparent about who they were, e.g. had an 'About us'
section, how to contact them and who the target audience
was. They also displayed responsible partnering, i.e. links
from their sites were mostly to reputable, non-profit gov-
ernmental and non-governmental sites. Some had links to
sponsoring organisations, including pharmaceutical com-
panies (see later) and two depression websites linked to
private psychiatry services. Few sites had explicit linking
policies and, where these existed, they covered the rules
for third parties to link to the patient organisation site
rather than the reverse. Less than 20% stated an editorial
policy describing how they derived and reviewed the
health information, or clearly and regularly indicated the
date of last update for their health-related content. Six of
the 69 websites (4 from the USA) subscribed to the HON-
Code [15] or similar code for quality online health infor-
mation (only four of these had a clear editorial policy).BMC Public Health 2006, 6:201 http://www.biomedcentral.com/1471-2458/6/201
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Transparency about funding was poor, with only a third of
websites clear on how the organisation derived all of its
funds (needed to indicate how funds are generated and
which corporations give funds but not the amounts
involved), although many solicited for donations and
members, and/or offered online merchandise. No major
differences were seen between countries although among
South African groups a smaller proportion solicited user
feedback about their website. In general South African
patient organisation websites were less developed than
their corresponding groups in the other countries.
General advertising
Only 3/69 patient organisation websites carried banner
advertising. One advertisement involved a pharmaceuti-
cal and we note it as an interesting example. The Arthritis
Australia website carries a promotional banner for Pain
Clear®, a branded generic version of paracetamol co-mar-
keted by Arthritis New Zealand and a marketing company.
A portion of the sale price goes to the patient organisation.
We were not sure whether this was a 'true' banner adver-
tisement since it resembles charity shopping.
We were also unsure about three instances where the
patient organisation (two osteoporosis and one heart)
carried what might be called 'banners' for their corporate
sponsors on the homepage, linking to the company's
website. These were described as a reward for the benefac-
tor rather than advertisements but carry an obvious pro-
motional advantage. A startling example was the Heart
Foundation of South Africa website, sponsored by a local
steakhouse (Figure 2).
Only 4/69 websites stated advertising policies (one in
Australia, 2 in the UK and one in the USA), including two
of those with banner advertisements. Four UK websites
clearly stated that any health-related information on the
website was independent from any funding which the
organisation might receive.
Annual reports and financial disclosure
Just over half (37; 54%) of sites had an 'up-to-date' annual
or financial report on the website (range 2003–2005).
Notably however, only 1 of 9 depression websites and 1
of 7 South African sites had an annual report (Table 3).
The mere presence of an annual report promises transpar-
ency and disclosure, but not all annual reports gave the
same quality of information. Formats varied widely –
some were little more than brief summaries of activities,
while others were large documents with patients' stories
and intended for soliciting donations. Acknowledgement
Flow diagram showing the selection process Figure 1
Flow diagram showing the selection process.BMC Public Health 2006, 6:201 http://www.biomedcentral.com/1471-2458/6/201
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Table 2: List of selected patient organisation websites.
Condition Organisation name URL Country Date of access1
Arthritis Arthritis Australia http://www.arthritisaustralia.com.au/ Australia 31 Dec. '05
Arthritis Society http://www.arthritis.ca Canada 2 Jan. '06
Arthritis Care http://www.arthritiscare.org.uk/ UK 2 Jan. '06
National Rheumatoid Arthritis Society http://www.rheumatoid.org.uk/ UK 2 Jan. '06
Arthritis Foundation http://www.arthritisfoundation.org/ USA 2 Jan. '06
Asthma Asthma Foundations of Australia http://www.asthmaaustralia.org.au/ Australia 3 Jan. '06
Asthma Society of Canada http://www.asthma.ca Canada 3 Jan. '06
Allergy/Asthma Information Association (AAIA) http://www.aaia.ca/ Canada 3 Jan. '06
Asthma UK http://www.asthma.org.uk/ UK 3 Jan. '06
British Lung Foundation http://www.britishlungfoundation.org.uk/ UK 3 Jan. '06
Asthma and Allergy Foundation of America (AAFA) http://www.aafa.org/ USA 3 Jan. '06
American Lung Association http://www.lungusa.org/ USA 4 Jan. '06
Cancer Cancer Council Australia http://www.cancer.org.au/ Australia 4 Jan. '06
Canadian Cancer Society http://www.cancer.ca Canada 4 Jan. '06
Cancer Association of South Africa http://www.cansa.org.za/ S Africa 4 Jan. '06
American Cancer Society http://www.cancer.org USA 4 Jan. '06
Lance Armstrong Foundation http://www.livestrong.org USA 4 Jan. '06
Cystic fibrosis Cystic Fibrosis Australia http://www.cysticfibrosisaustralia.org.au/ Australia 5 Jan. '06
Canadian Cystic Fibrosis Foundation http://www.ccff.ca Canada 5 Jan. '06
Cystic Fibrosis Trust http://www.cftrust.org.uk/ UK 5 Jan. '06
Cystic Fibrosis Foundation http://www.cff.org/ USA 5 Jan. '06
Cystic Fibrosis Worldwide http://www.cfww.org/ International 6 Jan. '06
Diabetes Diabetes Australia http://www.diabetesaustralia.com.au Australia 6 Jan. '06
Canadian Diabetes Association http://www.diabetes.ca Canada 6 Jan. '06
South African Diabetes Association http://home.intekom.com/buildlink/ips/sada/ S Africa 6 Jan. '06
Diabetes UK http://www.diabetes.org.uk UK 6 Jan. '06
Diabetes Insight http://www.diabetic.org.uk/ UK 6 Jan. '06
The Diabetes Research & Wellness Foundation http://www.drwf.org.uk/ UK 6 Jan. '06
American Diabetes Association http://www.diabetes.org USA 6 Jan. '06
International Diabetes Federation http://www.idf.org International 9 Jan. '06
Depression depressioNet http://www.depressionet.com.au/ Australia 9 Jan. '06
Mood Disorders Society of Canada http://www.mooddisorderscanada.ca Canada 9 Jan. '06
South African Depression and Anxiety group http://www.anxiety.org.za/ S Africa 9 Jan. '06
Depression Alliance http://www.depressionalliance.org/ UK 9 Jan. '06
SANE http://www.sane.org.uk UK 9 Jan. '06
Depression and Related Affective Disorders 
Association (DRADA)
http://www.drada.org USA 9 Jan. '06
Depression and Bipolar Support Alliance http://www.dbsalliance.org/ USA 10 Jan. '06
Freedom from Fear http://www.freedomfromfear.org USA 10 Jan. '06
Trapped Minds http://www.trappedminds.org International 10 Jan. '06
Befrienders Worldwide http://www.befrienders.org/ International 10 Jan. '06
Epilepsy Epilepsy Action Australia http://www.epilepsy.org.au/ Australia 10 Jan. '06
Epilepsy Australia http://www.epilepsyaustralia.org/ Australia 10 Jan. '06
Epilepsy Canada http://www.epilepsy.ca Canada 10 Jan. '06
Canadian Epilepsy Alliance http://www.epilepsymatters.com Canada 10 Jan. '06
Epilepsy South Africa http://www.epilepsy.org.za/index1.html S Africa 10 Jan. '06
Epilepsy Action UK http://www.epilepsy.org.uk/ UK 10 Jan. '06
Epilepsy Foundation http://www.efa.org USA 10 Jan. '06
International Bureau for Epilepsy (IBE) http://www.ibe-epilepsy.org/ International 10 Jan. '06
Heart disease National Heart Foundation Australia http://www.heartfoundation.com.au/ Australia 10 Jan. '06
Heart Support – Australia Ltd (HSA) http://www.heartnet.org.au/ Australia 10 Jan. '06
Heart and Stroke Foundation http://ww2.heartandstroke.ca Canada 10 Jan. '06
Heart Foundation of South Africa http://www.heartfoundation.co.za S Africa 10 Jan. '06BMC Public Health 2006, 6:201 http://www.biomedcentral.com/1471-2458/6/201
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of corporate sponsors varied greatly. Of the 37 reports,
eight gave no information, 15 listed the names only (two
only if the donation exceeded a certain threshold; some
describing which programme the money supported), the
Australian Heart Support report included a full page
advertisement for Merck Sharpe & Dohme (MSD), one
stated the donor's name and amount given (Epilepsy
Action Australia) and 12 gave bands or tiers indicating the
size of the donation, e.g. from $1,000 to $4,999. The
number of tiers varied from two (American Cancer Soci-
ety: $100,000 – $999,999 and $1,000,000 or more) to
eight (covering donations from $10,000 through $5 mil-
lion). The width and range of the tiers made it hard to esti-
mate even the approximate value of donations. Further,
these lists appeared to reflect only direct cash donations,
excluding research grants and fellowships, e.g. the Heart
and Stroke Foundation of Canada had 3 tiers for dona-
tions, but Pharma donations towards research fellowships
were acknowledged separately with the company logo
without mentioning the sum involved (a number of
patient organisations administer research grants and fel-
lowships, the money for which comes directly from
Pharma).
The financial summaries in the annual reports also varied.
Some organisations simply gave a gross figure for income
while others broke it down using an assortment of catego-
ries to integrate corporate donations. In only 7/37 cases
could the amount donated from corporate sponsors be
identified. Pharma's contribution was not specified and
whether sponsored research fellowships and scholarships
were included was seldom clear. Examples of non-Pharma
large corporate sponsors included computer manufactur-
ers, banks, telecommunication companies and many
local businesses. Non-profit trusts and foundations also
made donations to most of the patient groups.
Using the annual reports, we tried to describe the financial
status of the organisations and the contribution corporate
donations and membership fees make to total income.
The median net assets were $13 m (range $160,000 to
$1,500 m) with median annual revenue (total income) of
about $11 m (range $220,000 to $840 m). Cancer socie-
ties had by far the largest median assets ($630 m) and rev-
enue ($260 m) (Table 3). Patient organisations in the USA
had most assets and revenue, international organisations
least (Table 4). Corporate donations made up 5% (Cancer
Association of South Africa) to 65% (World Heart Federa-
tion) of annual income. Individual and corporate dona-
tions were about 70% of revenue on average. In our small
sample, heart disease patient groups relied more on cor-
porate donations than other disease societies.
Only two national organisations indicated the number of
individual members – 165 for one, 170,000 for another.
Associate members under umbrella patient organisations
ranged from 12 to 193. Most preferred to 'measure' them-
selves by the use of their telephone helplines or website
hits, but not all provided similar services to allow compar-
ison on this basis. Membership fees were a line item in the
financial summaries of 7 annual reports and contributed
a median 7% of annual income (range 2 – 38 %). Organ-
isation size in monetary terms seemed unrelated to indi-
cators of transparency or relationships with Pharma
companies (see below).
British Heart Foundation http://www.bhf.org.uk UK 11 Jan. '06
Heart UK http://www.heartuk.org.uk UK 11 Jan. '06
American Heart Association http://www.americanheart.org USA 11 Jan. '06
World Heart Federation http://www.worldheart.org International 11 Jan. '06
Osteoporosis Osteoporosis Australia http://www.osteoporosis.org.au Australia 11 Jan. '06
Osteoporosis Canada http://www.osteoporosis.ca Canada 11 Jan. '06
National Osteoporosis Foundation of South Africa http://www.osteoporosis.org.za S Africa 11 Jan. '06
National Osteoporosis Society http://www.nos.org.uk UK 11 Jan. '06
National Osteoporosis Foundation http://www.nof.org USA 11 Jan. '06
International Osteoporosis Foundation http://www.osteofound.org International 11 Jan. '06
Parkinson's 
disease
Parkinson Society Canada http://www.parkinson.ca/ Canada 11 Jan. '06
Parkinson Association South Africa http://www.parkinsons.co.za/ S Africa 11 Jan. '06
Parkinson's Disease Society http://www.parkinsons.org.uk/ UK 11 Jan. '06
National Parkinsons Foundation http://www.parkinson.org USA 11 Jan. '06
American Parkinson Disease Association, Inc. http://www.apdaparkinson.org/user/index.asp USA 11 Jan. '06
Parkinson's Action Network http://www.parkinsonsaction.org USA 11 Jan. '06
World Parkinson Disease Association http://www.wpda.org/ International 11 Jan. '06
1This is the date of first access. Website evaluators did not necessarily visit the site on the same day. Many sites were revisited to resolve differences 
between assessors.
Table 2: List of selected patient organisation websites. (Continued)BMC Public Health 2006, 6:201 http://www.biomedcentral.com/1471-2458/6/201
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Pharmaceutical company relationships and disclosure
Forty-five percent of 69 websites disclosed Pharma as a
source of funding. However, we found discrepancies
between the websites and the annual reports, with disclo-
sure sometimes in one but not the other. Similar discrep-
ancies were present for the number of Pharma donors
disclosed: more were named in the annual reports than on
the websites (median 6 vs. 1 respectively) (Table 3).
National patient organisations tended to underrepresent
Pharma companies on their websites while the opposite
was true for international patient organisations (Table 4).
We asked 28 of the 69 patient organisations which gave
no indication of Pharma funding to clarify this; nine
responded. Of these 4 had received Pharma donations, 5
said they had not.
Some annual reports mentioned a company repeatedly,
e.g. donations from both Pfizer Arizona and Pfizer Arkan-
sas, but this did not explain all the differences found. Sev-
enteen percent of websites noted Pharma-sponsored
events or programmes, which included research fellow-
ships and educational initiatives. One presented a compe-
tition to win a Caribbean cruise associated with an
analgesic medication (Arthritis Foundation, USA).
None of the websites clearly stated the proportion of
income derived from Pharma. Eleven (16%) gave some
indication of what the funding was used for, whether core
operations, education or research. Only 13% noted that
the funding was 'unrestricted', although in some addi-
tional cases, this was implied. One third of websites dis-
Screenshot of Heart Foundation of South Africa homepage with steakhouse sponsor logo Figure 2
Screenshot of Heart Foundation of South Africa homepage with steakhouse sponsor logo.BMC Public Health 2006, 6:201 http://www.biomedcentral.com/1471-2458/6/201
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played Pharma logos and had links to Pharma websites.
(Table 5). Some corporate introductions mentioned spe-
cific products likely to interest patients: for analgesia
(arthritis), anti-allergy (asthma), nicotine replacement
(cancer) and enzyme replacement (cystic fibrosis). No
websites claimed to have been established by a pharmaceu-
tical company. However, the World Parkinson's Disease
Association website noted: "In 1990, Merck, Sharpe and
Dohme International asked me to organize the first Inter-
national Lay Associations Conference" [16], and one
depression site (DepressioNet, Australia) claimed to owe
its survival to Wyeth, which it repaid by giving the com-
pany patient stories and advice, participating in sales team
and physician 'training', and with general promotional
support: "Wyeth believe that it is important that their
team who visit doctors and provide support materials etc
(sic) have an understanding of the issues for 'people like
us'. They seek to understand the needs of the end users of
their products and to help our medical professionals to
understand our needs (too)" [17].
Discussion
Our findings show that national and international patient
organisations are generally transparent on their websites
about who they are, their intentions and target audience.
However, many receive funding and possibly donations
in kind from pharmaceutical companies (Pharma) and
the extent of these relationships is incompletely acknowl-
edged.
There are natural expectations that patient organisations
and Pharma would have funding relationships [2,4] and
surveys suggest that more than half of health advocacy
groups receive money from Pharma [18,19]. However,
their ultimate beneficiaries are different – patient mem-
bers for the patient organisations, and shareholders for
Pharma – and conflicts of interest may arise. Just as gifts
(monetary or in kind) may induce feelings of loyalty and
indebtedness in physicians which can influence medical
decision-making [20,21] one may expect patient groups
also to be caught between two masters, perhaps more so
given the unequal nature of the relationship [4]. This is
especially true for those that feel they could not function
without financial help from industry [18] in the face of
increasing demands on their resources [22].
The use of patient organisations as part of an overall strat-
egy to influence authorities in the UK and EU has been
'exposed', [23] with recent examples. In 1999, Biogen
actively recruited public opinion as part of its Action to
Access campaign to coerce the National Health Service
(NHS) in the UK to allow interferon beta be prescribed to
multiple sclerosis patients, an illegal practice which the
Medicines Control Agency then stopped [4]. In Denmark,
local Pharma attempted to create a second migraine
patient association when the existing group refused inap-
propriate "assistance" from the pharmaceutical industry
[3]. A Dutch patient organisation for victims of inherited
cardiovascular disorders which received half of its funds
Table 3: Financial indicators and number of Pharma donors from annual reports and websites, analysed by disease.
Disease group & 
no. of patient 
organisation 
websites
Annual 
report 
available 
from website
Median Net 
assets 
($000,000s) 
[n]b
Median 
annual reve-
nuec 
($000,000s) 
[n]
Donationsd 
received as 
proportion of 
revenue; 
median [n]
Corporate 
donationse as 
prop. of reve-
nue; median 
[n]
Median no. 
(range) 
Pharma 
sponsors 
(Website)f
Median no. 
(range) 
Pharma 
sponsors 
(Ann. report)
Arthritis (5) 4 5.2 [4] 5.3 [3] 0.52 [3] 0.07 [1] 8.5 (5–10) 3.5 (0–19)
Asthma (7) 4 4.7 [4] 5.0 [4] 0.65 [4] 0.32 [2] 4 (0–14) 6.5 (0–9)
Cancer (5) 4 630.0 [3] 260.0 [4] 0.58 [3] 0.05 [1] 0 (0–2) 3 (0–8)
Cystic fibrosis (5) 4 1.0 [3] 6.3 [3] 0.55 [3] - 0 (0–2) 2.5 (0–10)
Diabetes (8) 4 20.7 [3] 98.0 [3] 0.77 [3] - 2 (0–15) 14.5 (1–29)
Depression (9) 1 1.1 [1] 3.0 [1] 0.92 [1] - 0 11
Epilepsy (8) 4 1.9 [3] 4.5 [4] 0.58 [4] - 0.5 (0–6) 3.5 (0–8)
Heart disease (8) 5 47.0 [3] 140.0 [4] 0.65 [4] 0.65 [1] 2 (0–7) 1 (0–38)
Osteoporosis (6) 4 7.2 [3] 4.9 [4] 0.66 [4] 0.38 [1] 3.5 (0–21) 11 (6–13)
Parkinson's (7) 3 22.0 [2] 9.5 [3] 0.78 [3] 0.07 [1] 1 (0–11) 7 (0–17)
Total (n = 69) 37 13.0 [29] 11.0 [33] 0.68 [32] 0.11 [7] 1 (0–21) 6 (0–38)
Notes:
aSee Methods for description of data standardisation across currency and year.
bNot all annual reports contained the necessary information; n = number of valid data entries.
cTotal income over the year of the annual report from all sources (excluding costs of fundraising activities).
dDonations includes legacies/bequests and membership dues, but excludes donated services and materials and special events.
eCorporate donations generally exclude donated services and materials, sponsored fellowships and research awards.
fOnly those websites having an annual report for comparisonBMC Public Health 2006, 6:201 http://www.biomedcentral.com/1471-2458/6/201
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from Pharma, was criticised for defending a company
(Pfizer) which had failed to inform doctors of a serious
side-effect of its cholesterol-lowering drug [24]. More
recently, while Roche has been largely out of the headlines
during the clamour for wider prescribing of its breast can-
cer drug trastuzumab (Herceptin), reports suggest that
they have been using patient groups to increase pressure
on national and local authorities to widen prescribing
[25]. These examples highlight how conflicts of interest
can occur. Full disclosure is necessary to allow patients
and other stakeholders to judge for themselves if they
matter in particular circumstances [20].
Website structural quality indicators showed that the
organisations were generally clear about themselves but
not their funding. The lack of clear editorial policies and
conflict of interest statements accords with the report that
declaration of competing interests are rare in Italian breast
cancer associations [11] and other international health
advocacy groups [18], suggesting that the problem
extends beyond disclosure on websites. Declaration of
interests by medical advisers and office bearers of patient
organisations is clearly also needed.
The websites were largely free from banner advertising,
and those which did carry advertising did not carry
Pharma advertisements. The absence of Pharma advertis-
ing is perhaps not surprising. Direct-to-consumer adver-
tising of prescription medicines is not legal in any of the
countries surveyed except the USA. In addition, national
patient organisations are likely to have developed multi-
ple sources of income and not want to give the impression
of relying on Pharma advertising revenue. The failure to
state an advertising policy on all but four of the websites
meant that the official patient organisation position on
advertising (on the website or in publications) was usu-
ally unknown.
One third of websites included 'advertisements' in the
form of corporate introductions and/or display of the
company's logo. Patient organisations may feel that they
need to give something to the companies in return for
their donation, but they should take care that such surrep-
titious advertising does not dent their independence or
integrity. To help patient groups think of the issues
involved and protect against conflicts of interest, we rec-
ommend that they develop and publish editorial and
advertising policies, and administrators and medical advi-
sors declare any Pharma-related interests.
Annual reports are often used to acknowledge and dis-
close sponsors by listing individual and corporate donors.
However, a lack of information prevented assessment of
the possible financial relations between Pharma and the
patient groups. This recently emerged about the American
Diabetic Association and National Osteoporosis Founda-
tion in the USA [26]. In our survey, at one extreme, 65%
of funding came from corporate donations suggesting that
there are patient organisations which depend so heavily
on this source that their independence could be threat-
ened. Smaller organisations reliant on Pharma donations
are more at risk and possibly more willing to push ethical
boundaries in an effort to increase their advocacy power
or to compete for donor attention [27]. These findings are
consistent with previous accounts of the annual reports of
national and international patient and health advocacy
groups from North America, Europe and Australia,
[18,22,28] and it is disappointing to note that there has
been no improvement over the years. Standardised report-
ing of donors and donations, including specific listing of
Table 4: Financial indicators and number of Pharma donors from annual reports and websites, analysed by country.
Country & no. 
of patient 
organisation 
websites
Annual 
report 
available from 
website
Median net 
assets 
($000,000s) 
[n]b
Median annual 
revenuec 
($000,000s) 
[n]
Donationsd 
received as pro-
portion of reve-
nue; median [n]
Corporate 
donationse as 
prop. of reve-
nue; median [n]
Median no. 
(range) 
Pharma spon-
sors (Website)f
Median no. 
(range) Pharma 
sponsors 
(Ann.report)
Australia (11) 4 12.0 [2] 51.0 [4] 0.79 [4] - 0 (0–9) 3 (1–7)
Canada (12) 6 - 5.7 [3] 0.70 [3] 0.22 [2] 1.5 (0–7) 7.5 (0–24)
S. Africa (7) 1 16.0 [1] 8.8 [3] 0.10 [1] 0.05 [1] 0 0
UK (15) 9 8.0 [9] 17.0 [8] 0.64 [8] 0.11 [1] 1 (0–8) 4 (0–9)
USA (16) 13 44.0 [13] 24.0 [13] 0.65 [12] 0.30 [2] 0 (0–15) 10 (0–38)
Global (8) 4 1.3 [4] 1.3 [4] 0.69 [4] 0.65 [1] 4.5 (0–21) 0.5 (0–13)
Total (69) [%] 37 [54%] 13.0 [29] 11.0 [33] 0.68 [32] 0.11 [7] 1 (0–21) 6 (0–38)
Notes:
aSee Methods for description of data standardisation across currency and year.
bNot all annual reports contained the necessary information; n = number of valid data entries.
cTotal income over the year of the annual report from all sources (excluding costs of fundraising activities).
dDonations includes legacies/bequests and membership dues, but excludes donated services and materials and special events.
eCorporate donations generally exclude donated services and materials, sponsored fellowships and research awards.
fOnly those websites having an annual report, for comparison.BMC Public Health 2006, 6:201 http://www.biomedcentral.com/1471-2458/6/201
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all Pharma benefactors, the amount or value of goods
donated, and the proportion of income derived from
Pharma should be implemented. The latter should be
available on the website as well as stated in annual and
financial reports.
The number of pharmaceutical companies providing
donations is also an important factor in assessing to what
influences an organisation is vulnerable [4], except in
cases where the group has more of an advocacy role than
direct patient care i.e. where it may be forwarding an
agenda common to Pharma in general (as was seen with
international patient organisations in this study). Disclo-
sure was inadequate both on the websites and in the
annual reports. Patient organisations should also be more
transparent about their size and how far they represent
patients. In this study, size varied a thousand-fold both in
terms of financial indicators and membership. Most web-
sites offered their services to non-members as well as
members and preferred to describe their outreach in terms
of number of website hits or telephone helpline calls, but
these do not represent individual users. Ideally, both
should be reported and governance structures described
to indicate the role and voting rights of members.
Pharma may itself seek to establish patient groups sympa-
thetic to its cause and products. Pharmaceutical compa-
nies played a part in establishing the International
Association of Patient Organizations (IAPO) and the Glo-
bal Alliance of Mental Illness Advocacy (GAMIAN); [4]
when the Danish migraine association refused to accept
funding Pharma tried to establish a rival migraine group
[3]. The finding that Pharma had a role in the establish-
ment of the World Parkinson's Disease Association was
thus not unique. Another example is the establishment of
an incontinence European Patient Association Network,
which according to the director of the Continence Foun-
dation UK followed "a meeting of patient groups arranged
by Pfizer" [29]. One may wonder which other patient
organisations groups owe their birth and life to Pharma.
The threat to the independence of patient organisations is
real – in addition to accidental conflicts of interest, they
may actually be targeted by Pharma. Some patient groups
have been seen as mouthpieces for Pharma [21,25,26,30],
addressing their lay members and regulators or insurance
bodies, or unsuspecting partners in disease mongering
[21,31]. They have a legitimate right to argue their case,
but they can be taken seriously only if they are seen to be
truly independent. It has been suggested that much of the
funding for patient organisations comes from marketing
rather than charity budgets, with funding from Merck and
Pfizer to the Arthritis Foundation in the USA doubling
when they launched their COX-2 inhibitors and falling
back once safety concerns became evident [30]. Gifts to
the organisations and their administrators can induce
feelings of loyalty and dependency leading to compro-
mised independence and modified practice as has been
observed with doctors who receive gifts from Pharma
[32]. Ethical codes guiding relationships between patient
organisations and pharmaceutical companies along the
lines of those for physicians would help to obviate poten-
tial conflicts of interest and assist smaller or younger
groups maintain their independence.
Some patient organisations recognise that care and trans-
parency is needed in interactions with Pharma [1,22,24].
Some openly declare their independence from Pharma
funding, e.g. the Insulin Dependent Diabetes Trust [33].
In the UK, 50 charities have so far joined the ImPACT
(Improving Accountability, Clarity and Transparency)
Coalition under the National Council for Voluntary
Organisations; they include about half a dozen patient
organisations. However, the main thrust of the transpar-
ency is related to communicating to members and donors
how funds are spent or invested, rather than how they are
Table 5: Indicators of interactions with pharmaceutical companies analysed by country.
Country & no. of 
patient organisation 
websites
Proportion of 
income from 
Pharma is 
clear
Use of 
Pharma 
funding is 
clear
Clear that 
Pharma 
funding is 
'unrestricted'
Pharma logos 
are present
Pharma 
introductions 
present
Evidence of 
Pharma 
sponsored 
events, etc.
Links to 
Pharma 
websites 
present
Australia (n = 11) 002411 3
Canada (n = 12) 021732 6
S. Africa (n = 7) 000300 2
UK (n = 15) 032512 4
USA (n = 16) 053225 5
Global (n = 8) 011202 1
Total (n = 69) n [%] 1 [1%] 11 [16%] 9 [13%] 23 [33%] 7 [10%] 12 [17%] 21 [30%]
Key: Pharma – pharmaceutical companies or industryBMC Public Health 2006, 6:201 http://www.biomedcentral.com/1471-2458/6/201
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raised [34]. In Australia, the Consumers' Health Forum
and Health Australia (the industry body in Australia) pro-
duced a joint guideline for cooperation between con-
sumer organisations and Pharma [35]. But this suggests
that sponsoring patient groups may increase the likeli-
hood that a company's products might be listed on the
national health reimbursement list – a clear industry bias
[36]. Although relationships between patient organisa-
tions and Pharma have caused concern for some years
[1,3,4,6,23], little has been done. Voluntary regulation
has been suggested, not least by the UK government in
response to the critical parliamentary report on the influ-
ence of the pharmaceutical industry in the UK [9]. This
was supposed to begin by April 2006 but has not hap-
pened. The slow pace of reform, the difficulties of fund-
raising [18,22] combined with increasing numbers of
charities wanting their share [22,37] and the tendency of
some patient groups to push ethical boundaries 'for the
cause' [27], suggest that self-regulation will be insuffi-
cient.
On the basis of our findings we recommend that:
 National charity regulators/independent monitoring
bodies should require standardised reporting by patient
organisations of corporate donations in annual and finan-
cial reports and on their websites, including full disclosure
of all Pharma donors and the nature and amounts of the
donations;
 National charity regulators/independent monitoring
bodies should oblige patient organisations and other
health charities with a web presence to maintain explicit
editorial and advertising policies on their websites;
 National charity regulators work with patient organisa-
tions to develop an ethical code of practice to guide rela-
tions with Pharma. Such an ethical code would give
guidance on acceptance of donations from Pharma, what
constitutes an acceptable gift to staff (travel, accommoda-
tion, food, etc.), and what, if any, are appropriate means
of rewarding Pharma and other corporate donors;
 Medical advisers of patient organisations should
declare any possible conflicts of interest to the organisa-
tion's trustees and on the website.
Limitations of our study were:
The survey was restricted to major national and interna-
tional patient organisations with websites. Although
health informatics is an increasingly important means for
patient groups to reach communities and their members,
size and skills may prevent them maintaining a website.
Organisations without a web presence were not repre-
sented and may differ from those included by being
smaller and poorer. The focus on websites also ignored
print or other material which patient organisations dis-
tribute and in which pharmaceutical companies may
advertise. The fact that the study is a one-off cross-sec-
tional survey of a rapidly changing medium of communi-
cation must also be borne in mind.
Patient organisations which focus more on advocacy than
on actual patient care may also have been missed, as they
may not maintain a website but rather directly approach
their target audience, i.e. policymakers and regulators. If
these are more influenced by Pharma, our sample could
not show it. We also could not examine donations in kind
or other forms of financial support since this not detailed
on the websites or in the annual reports. Exclusion of
Pharma Foundations may underrepresent the influence
which Pharma has on patient organisations, e.g. both
GlaxoSmithKline (GSK) and GlaxoSmithKline Founda-
tion were listed in the top band (>$100,000) of donors to
the National Parkinson Foundation.
Conclusion
Patient organisations are clear about their purpose on
their websites, but they do not disclose competing inter-
ests that they may have with pharmaceutical industry
donors. While explicit advertising is generally absent,
some patient organisations help companies by displaying
logos and corporate advertisements. The lack of clear edi-
torial and advertising policies makes this easier. Informa-
tion about sponsors in annual reports often differs from
that given on the website, and financial summaries rarely
allow assessment of potential conflicts of interest. Greater
guidance and disclosure is required if patient organisa-
tions are to remain independent and truly represent the
views of patients.
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